NCT04430452
- Conditions
- Adenocarcinoma, Advanced Hepatocellular Carcinoma, Carcinoma, +15 more
- Locations
-
- University of California, San Francisco San Francisco, California, United States
Clinical trial condition
Stage III Hepatocellular Carcinoma AJCC v8
Explore clinical trials studying Stage III Hepatocellular Carcinoma AJCC v8. Study availability and eligibility vary by location and protocol.
22 public trials
12 recruiting studies
Stage III Hepatocellular Carcinoma AJCC v8 trial results
NCT05168163
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +17 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Cleveland Clinic Weston Florida Weston, Florida, United States
- University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
Not Yet Recruiting
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
NCT07511504
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
- Locations
-
- OHSU Knight Cancer Institute Portland, Oregon, United States
NCT05176223
- Conditions
- Adenocarcinoma, Advanced Hepatocellular Carcinoma, Carcinoma, +12 more
- Locations
-
- Mayo Clinic in Rochester Rochester, Minnesota, United States
NCT04022746
- Conditions
- Adenocarcinoma, Advanced Adult Hepatocellular Carcinoma, Carcinoma, +15 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT03439891
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +15 more
- Locations
-
- University of California, Davis Sacramento, California, United States
- University of California, San Francisco San Francisco, California, United States
Completed
Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma
NCT01176604
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +15 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
NCT05194293
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
- Medical College of Wisconsin Milwaukee, Wisconsin, United States
Active, Not Recruiting
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
NCT04175912
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +24 more
- Locations
-
- Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
Active, Not Recruiting
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
NCT04514484
- Conditions
- Adenocarcinoma, Adnexal Diseases, Advanced Differentiated Thyroid Gland Carcinoma, +141 more
- Locations
-
- Northwestern University Chicago, Illinois, United States
- Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
- University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States